drugset / Trial / NCT03246113

Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma

NCT03246113

Phase 1 Terminated 1 enrolled New York State Psychiatric Institute
NaSingle-groupOpen-labelTreatment

Summary

The goal of this single arm Phase I feasibility study is to investigate the tolerability of cannabis with concurrent chemoradiation in the treatment of glioblastoma multiforme (GBM). A strain of cannabis provided by The National Institute of Drug Abuse (NIDA) that has a high concentration of cannabidiol (CBD) and a low concentration of THC (relative to average street cannabis) will be tested in order to maximize clinical efficacy while minimizing intoxicating side effects in this medically-ill population.

Timeline

Start
2018-03-19
Primary completion
2019-05-09
Completion
2019-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cannabis Traditional medicine (herbal / TCM) 0.5 unknown Inhaled
Subject Cannabis Traditional medicine (herbal / TCM) 2 unknown Inhaled
Background Temozolomide Small molecule Oral

Indications